Race Oncology CEO Daniel Tillett speaks with Proactive’s Andrew Scott about the company’s initiation of a drug discovery program to build on the strength and knowledge of FTO – the company’s target protein – and ALKBH5 inhibitors. The program will not only give Race the ability to develop a version of current drug Zantrene, but also other drugs which take the company into other disease areas beyond cancer including diabetes. Race is working with Monash University’s Monash Fragment Platform (MFP) and will own all the intellectual property developed in the project.
#RaceOncology #asx #ProactiveInvestors #biotech

свернуть